Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 5/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183110 | 0.89 | MAPK14 (0.55) | MAPK14CYP3A4KDM4EMAPTTGFBR1 | |
| SCHEMBL6182973 | 0.88 | MAPK14 (0.64) | MAPK14CYP3A4KDM4EMAPTIDO1 | |
| SCHEMBL6183296 | 0.85 | MAPK14 (0.50) | MAPK14CYP3A4KDM4EMAPTIDO1 | |
| SCHEMBL6183892 | 0.82 | TGFBR1 (0.54) | MAPK14CYP3A4IDO1TGFBR1 | |
| SCHEMBL4072430 | 0.79 | TGFBR1 (0.43) | MAPK14CYP3A4TGFBR1 | |
| SCHEMBL20873816 | 0.79 | SLC9A1 (0.58) | SLC9A1KEAP1TDO2MAPK1 | |
| SCHEMBL29717660 | 0.79 | SLC9A1 (0.58) | SLC9A1KEAP1TDO2MAPK1 | |
| SCHEMBL6184801 | 0.77 | MAPK14 (0.46) | MAPK14CYP3A4KDM4EMAPTIDO1 | |
| SCHEMBL6182328 | 0.76 | MAPK14 (0.62) | MAPK14CYP3A4KDM4EMAPTTGFBR1 | |
| SCHEMBL18041963 | 0.75 | MAPK14 (0.90) | MAPK14CYP3A4KDM4EMAPTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-107406412-B | TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| EP-1247810-B1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6664395-B2 | Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia | PFIZER INC | 2003-12-16 | — | — | US | disclosed |
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1247810-A1 | Novel benzotriazoles anti-inflammatory compounds | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | MAPK1, JAK1, RUNX1 | MAPK14 27/4885CYP3A4 3334/4885KDM4E 4254/4885 |
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2266/4885CYP3A4 3457/4885KDM4E 1524/4885 |
| US-20200031832-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2266/4885CYP3A4 3457/4885KDM4E 1524/4885 |
| US-20180127426-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2266/4885CYP3A4 3457/4885KDM4E 1524/4885 |
| US-10287295-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2085/4885CYP3A4 3442/4885KDM4E 1317/4885 |
| US-20160257690-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2266/4885CYP3A4 3457/4885KDM4E 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.